High Prescription Rate of Medications With Rifampin Drug–drug Interactions in Patients With Diabetic Foot Osteomyelitis: Should Rifabutin Be Included in Clinical Trials for Adjunctive Therapy?
Year: 2024
Type: article
Study design: Observational Study
Abstract: Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug-drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug-drug interactions, would be easier to implement in practice.
Source: Open Forum Infectious Diseases
DOI: 10.1093/ofid/ofae582
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,256
Award: G6857360495
OpenAlex ID: W4403338074